Who are CT-P51's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bevacizumab (Avastin®), Intravitreal injection of bevacizumab, Intravitreal Bevacizumab IVB, Intravitreal bevacizumab, Subconjunctival Bevacizumab, Bevacizumab (Bev).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ct-p51.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CT-P51 — Competitive Intelligence Brief

CT-P51 (CT-P51) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody); bevacizumab biosimilar. Area: Oncology.

phase 3 VEGF inhibitor (monoclonal antibody); bevacizumab biosimilar VEGF (Vascular Endothelial Growth Factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CT-P51 (CT-P51) — Celltrion. CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CT-P51 TARGET	CT-P51	Celltrion	phase 3	VEGF inhibitor (monoclonal antibody); bevacizumab biosimilar	VEGF (Vascular Endothelial Growth Factor)
Bevacizumab (Avastin®)	Bevacizumab (Avastin®)	Hanny Al-Samkari, MD	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Intravitreal injection of bevacizumab	Intravitreal injection of bevacizumab	Barnes Retina Institute	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (vascular endothelial growth factor)
Intravitreal Bevacizumab IVB	Intravitreal Bevacizumab IVB	Khyber Teaching Hospital	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Intravitreal bevacizumab	Intravitreal bevacizumab	University of Sao Paulo	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Subconjunctival Bevacizumab	Subconjunctival Bevacizumab	Grewal Eye Institute	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Bevacizumab (Bev)	Bevacizumab (Bev)	Eli Lilly and Company	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody); bevacizumab biosimilar class)

Amgen · 1 drug in this class
Celltrion · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CT-P51 — Competitive Intelligence Brief. https://druglandscape.com/ci/ct-p51. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab